Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MASP2 | O00187 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29485930 | 1.00 | MASP2 (0.51) | MASP2F2ATMPTGESMAPT | |
| SCHEMBL29485992 | 0.81 | LMNA (0.56) | MAPTNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL22748314 | 0.81 | LMNA (0.56) | MAPTNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL7982492 | 0.80 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL22748145 | 0.78 | PLK1 (0.47) | ATMMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3451299 | 0.77 | MASP2 (0.51) | MASP2F2MAPTNPC1RAB9A | |
| SCHEMBL10665310 | 0.76 | CYP1A2 (0.60) | MASP2F2MAPTNPC1RAB9A | |
| SCHEMBL22748931 | 0.75 | MAPT (0.48) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30029803 | 0.75 | MAPT (0.48) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8067143 | 0.75 | MAPT (0.57) | MASP2F2MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403144-B2 | HECT E3 ligase inhibitors and uses thereof | IFOM —FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2025-09-02 | — | — | US | disclosed |
| EP-3976185-B1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM ST FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS (IT) | 2024-02-14 | — | — | EP | disclosed |
| US-20220339163-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2022-10-27 | — | — | US | disclosed |
| EP-3976185-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM - Fondazione Istituto FIRC di Oncologia Molecolare (IT) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020245213-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339163-A1 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | NEDD4, ITCH, UBE3A | MASP2 2112/4885F2 4877/4885ATM 3479/4885 |
| US-12403144-B2 | HECT E3 ligase inhibitors and uses thereof | NEDD4, ITCH, UBE3A | MASP2 2112/4885F2 4877/4885ATM 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.